Cor pulmonale und pulmonale Hypertonie

Galiè N, Hoeper MM, Humbert M et al (2009) Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 30:2493–2537 Simonneau G, Gatzoulis MA, Adatia I et al (2013) Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 62(Suppl D):D34–D41 Simonneau G, Robbins IM, Beghetti M et al (2009) Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 54(Suppl S):S43–S54 Tuder RM, Archer SL, Dorfmüller P et al (2013) Relevant issues in the pathology and pathobiology of pulmonary hypertension. J Am Coll Cardiol 62(Suppl D):D4–D12 Soubrier F, Chung WK, Machado R et al (2013) Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol 63(Suppl D):D13–D21 McGoon M, Benza RL, Escribano-Subias P et al (2013) Pulmonary arterial hypertension: epidemiology and registries. J Am Coll Cardiol 62(Suppl D):D51–D59 Rich S, Dantzker DR, Ayres SM et al (1987) Primary pulmonary hypertension: a national prospective study. Ann Intern Med 107:216–223 D’Alonzo GE, Barst RJ, Ayres SM et al (1991) Survival in patients with primary pulmonary hypertension. Ann Intern Med 115:343–349 Humbert M, Sitbon O, Chaouat A et al (2010) Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 122:156–163 Hoeper MM, Huscher D, Ghofrani HA et al (2013) Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry. Int J Cardiol 168:871–880 Hoeper M, Bogaard HJ, Condliffe R et al (2013) Definition and diagnosis of pulmonary hypertension. J Am Coll Cardiol 62(Suppl D):D42–D50 Ryan JJ, Rich JD, Thiruvoipati T et al (2012) Current practice for determining pulmonary capillary wedge pressure predisposes to serious errors in the classification of patients with pulmonary hypertension. Am Heart J 163:589–594 Rosenkranz S, Behr J, Ewert R et al (2011) Rechtherzkatheter-Untersuchung bei pulmonaler Hypertonie. Dtsch Med Wochenschr 136:2601–2620 Barst RJ, Gibbs SR, Ghofrani HA et al (2009) Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 54(Suppl S):S78–S84 Galiè N, Corris PA, Frost A et al (2013) Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol 62(Suppl D):D60–D72 Bolli MH, Boss C, Binkert C et al (2012) The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N’-propylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist. J Med Chem 55:7849–7861 Gatfield J, Mueller Grandjean C, Sasse T et al (2012) Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells. PLoS One 7:e47662 Iglarz M, Binkert C, Morrison K et al (2008) Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther 327:736–745 Pulido T, Adzerikho I, Channick RN et al (2013) Macitentan and morbidity and mortality in pulmonary arterial hypertension. New Engl J Med 369:809–818 Evgenov OV, Pacher P, Schmidt PM et al (2006) NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov 5:755–768 Ghofrani HA, Hoeper M, Halank M et al (2010) Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension. A phase II study. Eur Respir J 36:792–799 Ghofrani HA, Galiè N, Grimminger F et al (2013) Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 369:330–340 Ghofrani HA, D’Armini AM, Grimminger F et al (2013) Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med 369:319–329 Freyhaus H ten, Dumitrescu D, Berghausen E (2012) Imatinib mesylate for pulmonary arterial hypertension. Exp Opin Investig Drugs 21:119–134 Hoeper MM, Barst RJ, Bourge RC et al (2013) Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation 127:1128–1138 Olsson KM, Delcroix M, Ghofrani HA et al (2014) Anticoagulation and survival in pulmonary arterial hypertension: results from the COMPERA registry. Circulation 129:57–65 Bursi F, McNallan SM, Redfield MM et al (2012) Pulmonary pressures and death in heart failure. J Am Coll Cardiol 59:222–231 Lam CS, Roger VL, Rodeheffer RJ et al (2009) Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol 53:1119–1126 Ghio S, Gavazzi A, Campana C et al (2001) Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol 37:183–188 Abraham WT, Adamson PB, Bourge RC et al (2011) Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet 377:658–666 Naejie R, Vachiéry JL, Vanderpool R (2013) The transpulmonary pressure gradient for the diagnoisis of pulmonary vascular disease. Eur Respir J 41:217–223 Gerges C, Gerges M, Lang MB et al (2013) Diastolic pulmonary vascular pressure gradient. A predictor of prognosis in out-of-proportion pulmonary hypertension. Chest 143:758–766 Rosenkranz S, Bondermann D, Buerke M et al (2011) Pulmonary hypertension due to left heart disease: updated Recommendations of the Cologne Consensus Conference 2011. Int J Cardiol 154(Suppl 1):S34–S44 Vachiery JL, Adir Y, Barbera JA et al (2013) Pulmonary hypertension due to left heart diseases. J Am Coll Cardiol 62(Suppl D):D100–D108 Guazzi M, Vicenzi M, Arena R, Guazzi MD (2011) Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation 124:164–174 Dumitrescu D, Seck C, Möhle L et al (2012) Therapeutic potential of sildenafil in patients with heart failure and reactive pulmonary hypertension – results of compassionate care treatment. Int J Cardiol 154:205–206 Redfield MM, Chen HH, Borlaug BA et al (2013) Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 309:1268–1277 Bonderman D, Ghio S, Felix SB et al (2013) Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study. Circulation 128:502–511 Hoeper MM, Andreas S, Bastian A et al (2011) Pulmonary hypertension due to chronic lung disease: updated Recommendations of the Cologne Consensus Conference 2011. Int J Cardiol 154(Suppl 1):S45–S53 Boerrigter BG, Bogaard HJ, Trip P et al (2012) Ventilatory and cardiocirculatory exercise profiles in COPD: the role of pulmonary hypertension. Chest 142:1166–1174 Seeger W, Adir Y, Barbera JA et al (2013) Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol 62(Suppl D):D109–D116 Mayer E, Jenkins D, Lindner J et al (2011) Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. J Thorac Cardiovasc Surg 141:702–710 Kim NH, Delcroix M, Jenkins DP et al (2013) Chronic thromboembolic pulmonary hypertension. J Am Coll Cardiol 62(Suppl D):D92–D99 Madani MM, Auger WR, Pretorius V et al (2012) Pulmonary endarterectomy: recent changes in a single institution’s experience of more than 2,700 patients. Ann Thorac Surg 94:97–103